Printer Friendly

Halozyme announces notice of allowance for patent claims to second human enzyme.

Halozyme Therapeutics, Inc. (San Diego, CA), a biopharmaceutical company developing and commercializing recombinant human enzymes, announced that the United States Patent Trademark Office has given a notice of allowance to both natural and recombinant forms of HTI-101, a second enzyme in Halozyme's pipeline. The patent is licensed exclusively to Halozyme from the University of California, San Francisco. The new patent claims for HTI-101 are directed to a human enzyme normally found in the bloodstream with a mechanism of action that is distinct from Halozyme's FDA approved rHuPH20 enzyme. This new enzyme may prove useful for additional therapeutic applications. Halozyme is currently conducting pre-clinical work with HTI-101 in the fields of oncology and inflammation.

"We are pleased to add these new natural and recombinant composition of matter claims in the '283 patent to Halozyme's growing human enzyme intellectual property estate," said Gregory Frost, PhD, Halozyme's Chief Scientific Officer. "This second enzyme can be readily channeled into our commercially validated molecular engineering systems and mammalian manufacturing processes, and fits nicely with Halozyme's demonstrated ability to develop and commercialize recombinant human enzymes."

Halozyme is a biopharmaceutical company developing and commercializing recombinant human enzymes for the infertility, palliative care, and oncology markets. The company's portfolio of products is based on intellectual property covering the family of human enzymes known as hyaluronidases. Halozyme's recombinant human enzymes may replace current animal slaughterhouse-derived extracts that carry potential risks of animal pathogen transmission and immunogenicity. The company has received FDA approval for two products: Cumulase, the first and only recombinant human hyaluronidase for cumulus removal in the IVF process; and Hylenex, for use as an adjuvant to increase the absorption and dispersion of other injected drugs. The versatility of the first enzyme, rHuPH20, enables Halozyme to develop the product as a medical device, drug enhancement agent, and therapeutic drug.

Halozyme Therapeutics, Inc.

+1-858-794-8889

www.halozyme.com
COPYRIGHT 2006 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Date:Jan 1, 2006
Words:308
Previous Article:Patent office awards 7 millionth patent to DuPont for bio-based material.
Next Article:Roche and Applied Biosystems settle PCR litigation with Bio-Rad.
Topics:


Related Articles
Enzyme offers promise of Alzheimer's drugs.
GlycoDesign receives patent allowance for cancer drug.
HALOZYME THERAPEUTICS REITERATES ENHANZE SC TIMELINE.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters